Risk-benefit analysis of adalimumab versus traditional non-biologic therapies for patients with Crohn's disease
Inflammatory Bowel Disease, 06/03/2010
Clinical Article
Loftus EV et al. – Adalimumab demonstrated greater benefits and lower rates of AEs versus traditional non–biologic therapies for patients with moderately to severely active CD who were refractory to non–biologic therapies.



